265643-79-6Relevant articles and documents
Substances for treatment or relief of pain
-
Paragraph 0261; 0262, (2016/01/25)
Disclosed is the use of an inverse agonist for alpha-subunit-containing gamma-aminobutyric acid A receptor in the preparation of a medicine for the prevention, alleviation, or treatment of pain.
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA α5 receptors with cognition enhancing properties
Chambers, Mark S.,Atack, John R.,Carling, Robert W.,Collinson, Neil,Cook, Susan M.,Dawson, Gerard R.,Ferris, Pushpindar,Hobbs, Sarah C.,O'Connor, Desmond,Marshall, George,Rycroft,MacLeod, Angus M.
, p. 5829 - 5832 (2007/10/03)
(3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2, 4-triazol-5-ylmethoxy)pyrazolo[1,5-d][1,2,4]triazine (13) has been identified as a functionally selective, inverse agonist at the benzodiazepine site of GABAA α5 receptors. 13 is orall
Pyrazolo-triazine derivatives as ligands for GABA receptors
-
, (2008/06/13)
Compounds according to Formula (I): or a salt or prodrug thereof, have good affinity as ligands for the alpha2 and/or alpha3 subunit of the human GABAAreceptor and are useful for treatment of disorders of the central nervous system, including a
Pyrazolo[1,5-d][1,2,4] triazines for enhancing cognition
-
, (2008/06/13)
Compounds according to Formula (I) or a salt thereof are GABA-A Alpha 5 ligands useful for enhancing cognition: STR1